Navigation Links
Angioplasty Not Always Worth the Price
Date:11/12/2008

Cost analysis finds procedure often doesn't bring enough benefit to offset expense

WEDNESDAY, Nov. 12 (HealthDay News) -- The high cost of angioplasty may not justify the marginal benefit, a new study suggests.

Researchers reporting at the American Heart Association's (AHA) annual scientific sessions in New Orleans found that adding angioplasty to optimal medical therapy improved angina-related symptoms in some patients but "at a cost generally considered to be prohibitive as a routine initial management strategy."

"This is an important trial," said Dr. Sidney Smith, chairman of the AHA/American College of Cardiology task force on guidelines. "More and more as we develop guidelines and treatment strategies for patients, the cost is important, and in this particular trial, it appeared the use of stents and additional angina associated with that was expensive."

But this doesn't mean the procedure shouldn't be performed.

"Cost should not be a total roadblock," Smith said. "It should be an incentive to do things in a better way, by targeting the population or making the procedure or drug in a less expensive way. . . . Let's find a way to fix the cost."

Currently, cost analyses of procedures and medications tend to lag behind studies of their effectiveness and place in the practice of medicine.

Prior research suggests that interventional procedures to re-open coronary arteries after blockages, when used with up-to-date medical therapy, does not actually reduce the incidence of cardiovascular events any more than medication alone.

The original trial, known as COURAGE, compared adding angioplasty to best medical therapy and lifestyle interventions to medical therapy alone in reducing the risk of dying or having a heart attack. It found little difference between the two.

According to the AHA, angioplasty involves inserting a thin tube from a groin artery to the blocked artery in the heart. Doctors then inflate a small balloon at the tip of the tube to widen the vessel, insert a stent and restore blood flow.

This secondary analysis involved 2,287 patients who were followed for a median of 4.6 years. Researchers compared the cost of treating angina in Canada, the U.S. non-VA health system and the U.S. VA health system.

Quality of life results were similar among groups, although physical limitation results did vary. The net benefit here ranged from less than 1 percent in U.S. non-VA hospitals to 18 percent in Canadian facilities.

When measured by the frequency of chest pain, researchers calculated the absolute net benefit to be 6.85 percent, with an average added cost for the PCI of $10,107 per patient.

The added cost of PCI ranged from a low of $5,906 per patient in Canada to a high of $15,896 in U.S. VA hospitals.

The overall cost per patient related to angina frequency (as assessed by a patient questionnaire) ranged from a low of $55,700 in Canada (the average in Canada was $118,740) to a high of more than $1 million at U.S. non-VA facilities. The analysis was done in 2004 U.S. dollars.

More information

The American Heart Association has more on angioplasty.



SOURCES: Sidney Smith, Jr., M.D., past president, American Heart Association, and professor, medicine, University of North Carolina, Chapel Hill; Nov. 12, 2008, presentation, American Heart Association annual scientific sessions, New Orleans


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hispanics less likely to have repeat revascularizations 1 year after angioplasty
2. Florida study finds barriers to angioplasty for life-threatening heart attacks
3. Angioplasty Scoring System Predicts Risk of Death
4. Angioplasty No Better Than Drug Treatment in Long Run
5. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
6. Off-Hours Heart Patients Less Likely to Get Angioplasty
7. State Report Ranks LIJ as New Yorks Best Hospital for Angioplasty Survival
8. Angioplasty Proves Reasonable Alternative to Bypass Surgery
9. Anticoagulant Drugs Had Similar Outcomes After Angioplasty
10. Comparison of anticoagulants for angioplasty show similar outcomes
11. The Elderly Can Be Candidates for Angioplasty, Stenting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Angioplasty Not Always Worth the Price
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical ... recently joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, ... excited to add this excellent dermatology practice to our group’s medical services,” explains ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion ... deck space. Since the lift is mounted on wheels, it can be wheeled out of ... down kit, to fasten to the deck. "We have transformed the feedback from customers into ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... ... International Protein, a company based out of Australia that focuses on developing ... trade show in Hilton Head, SC. , International Protein was founded by Christine ... of products that would elevate her fitness regime. At this ECRM trade show, Envall ...
(Date:1/20/2017)... ... , ... “Mary Magdalene: Grace is Greater than Sin”: a unique and ... Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation of published ... with countless women who had little knowledge of the female characters portrayed in the ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 20, 2017 ResMed (NYSE: RMD ), BMC ... Winter Haven, Florida ) today announced they have agreed on ... 3B will be permitted to sell their existing products in exchange ... settlement payment to 3B to close the Florida ... an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... 20, 2017  Today, during a plenary ... Pathways in Immunology, Growth Disorders and Cancer," ... INFI ) presented preclinical data for ... selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical data showed ... resistance to checkpoint inhibition by remodeling the ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal ... report to their offering. ... The global clinical laboratory testing market is expected ... innovative solutions on the grounds of maximum efficiency and minimum error ...
Breaking Medicine Technology: